Breaking News

MannKind Ends Afrezza License with Sanofi

Will transition development and commercialization to MannKind

MannKind Corp. has terminated its license and collaboration agreement with Sanofi-aventis U.S. for the development and commercialization of Afrezza (insulin human) Inhalation Powder. The companies will transition the development and commercialization of Afrezza from Sanofi to MannKind within 180 days.
 
MannKind is reviewing its strategic options for Afrezza as a result of the termination of the Sanofi collaboration.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters